Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis

Blood

Volumn 122, Issue 16, 2013, Pages 2777-2783

  Lechtenberg, Bernhard C ^a   Murray Rust, Thomas A ^a   Johnson, Daniel J D ^a   Adams, Ty E ^a   Krishnaswamy, Sriram ^b   Camire, Rodney M ^b   Huntington, James A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; MEIZOTHROMBIN; PROTHROMBIN; PROTHROMBINASE COMPLEX; SNAKE VENOM; THROMBIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING SITE; BLOOD CLOTTING; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; ENZYME ACTIVE SITE; MEMBRANE BINDING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDONAJA TEXTILIS; SITE DIRECTED MUTAGENESIS; SNAKE; STRUCTURE ANALYSIS;

EID: 84887052679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-511733     Document Type: Article

References (48)

1. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114(12):2367-2374.
2. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34-45.
3. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science. 1964;145(3638):1310-1312.
4. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature. 1964;202:498-499.
5. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood. 2005;106(8):2605-2612.
6. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.
7. Krishnaswamy S. Prothrombinase complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation. J Biol Chem. 1990;265(7):3708-3718.
8. Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem. 1986;261(19):8977-8984.
9. Hacisalihoglu A, Panizzi P, Bock PE, Camire RM, Krishnaswamy S. Restricted active site docking by enzyme-bound substrate enforces the ordered cleavage of prothrombin by prothrombinase. J Biol Chem. 2007;282(45):32974- 32982.
10. Reza MA, Minh Le TN, Swarup S, Manjunatha Kini R. Molecular evolution caught in action: gene duplication and evolution of molecular isoforms of prothrombin activators in Pseudonaja textilis (brown snake). J Thromb Haemost. 2006;4(6):1346-1353.
11. Bos MH, Boltz M, St Pierre L, et al. Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations. Blood. 2009;114(3):686-692.
12. Lechtenberg BC, Johnson DJ, Freund SM, Huntington JA. NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation. Proc Natl Acad Sci USA. 2010;107(32):14087-14092.
13. Leslie AGW. Joint CCP4 + ESF-EAMCB. Newsl Protein Crystallogr. 1992;26.
14. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005;61(Pt 4):458-464.
15. Wei A, Alexander RS, Duke J, Ross H, Rosenfeld SA, Chang CH. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. J Mol Biol. 1998;283(1):147-154.
16. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53(Pt 3):240-255.
17. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486-501.
18. Sánchez R, Sali A. Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol Biol. 2000;143:97-129.
19. Padmanabhan K, Padmanabhan KP, Tulinsky A, et al. Structure of human des (1-45) factor Xa at 2.2 A resolution. J Mol Biol. 1993;232(3):947-966.
20. De Lano WL. The PyMOL molecular graphics system; 2002. Available at: http://www.pymol.org/.
21. Bos MH, Camire RM. A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem. 2012;287(31):26342-26351.
22. Fehlhammer H, Bode W, Huber R. Crystal structure of bovine trypsinogen at 1-8 A resolution. II. Crystallographic refinement, refined crystal structure and comparison with bovine trypsin. J Mol Biol. 1977;111(4):415-438.
23. Steen M, Tran S, Autin L, Villoutreix BO, Tholander AL, Dahlbäck B. Mapping of the factor Xa binding site on factor Va by site-directed mutagenesis. J Biol Chem. 2008;283(30):20805-20812.
24. Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem. 1997;272(33):20678-20683.
25. Guinto ER, Esmon CT. Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem. 1984;259(22):13986-13992.
26. Steen M, Villoutreix BO, Norstrøm EA, Yamazaki T, Dahlbäck B. Defining the factor Xa-binding site on factor Va by site-directed glycosylation. J Biol Chem. 2002;277(51):50022-50029.
27. Bakker HM, Tans G, Thomassen MC, et al. Functional properties of human factor Va lacking the Asp683-Arg709 domain of the heavy chain. J Biol Chem. 1994;269(32):20662-20667.
28. Toso R, Camire RM. Role of Hirudin-like factor Va heavy chain sequences in prothrombinase function. J Biol Chem. 2006;281(13):8773-8779.
29. Li W, Adams TE, Nangalia J, Esmon CT, Huntington JA. Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex. Proc Natl Acad Sci USA. 2008;105(12):4661-4666.
30. Rezaie AR. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J Biol Chem. 2000;275(5):3320-3327.
31. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA. 1995;92(21):9796-9800.
32. Husten EJ, Esmon CT, Johnson AE. The active site of blood coagulation factor Xa. Its distance from the phospholipid surface and its conformational sensitivity to components of the prothrombinase complex. J Biol Chem. 1987;262(27):12953-12961.
33. Isaacs BS, Husten EJ, Esmon CT, Johnson AE. A domain of membrane-bound blood coagulation factor Va is located far from the phospholipid surface. A fluorescence energy transfer measurement. Biochemistry. 1986;25(17):4958-4969.
34. Pozzi N, Chen Z, Gohara DW, Niu W, Heyduk T, Di Cera E. Crystal structure of prothrombin reveals conformational flexibility and mechanism of activation [published online ahead of print June 17, 2013]. J Biol Chem.
35. Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry. 1992;31(9):2554-2566.
36. Chen Z, Pelc LA, Di Cera E. Crystal structure of prethrombin-1. Proc Natl Acad Sci USA. 2010;107(45):19278-19283.
37. Everse S, Adams T, Mann K. A molecular model of the human prothrombinase complex. In: Tanaka K, Davie E, Ikeda Y, Iwanaga S, Saito H, Sueishi K, eds. Recent Advances in Thrombosis and Hemostasis 2008. Kyoto, Japan: Springer; 2008:107-132
38. Blostein MD, Rigby AC, Jacobs M, Furie B, Furie BC. The Gla domain of human prothrombin has a binding site for factor Va. J Biol Chem. 2000;275(48):38120-38126.
39. Orcutt SJ, Krishnaswamy S. Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin. J Biol Chem. 2004;279(52):54927-54936.
40. Bianchini EP, Orcutt SJ, Panizzi P, Bock PE, Krishnaswamy S. Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase. Proc Natl Acad Sci USA. 2005;102(29):10099-10104.
41. Brufatto N, Nesheim ME. Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process. J Biol Chem. 2003;278(9):6755-6764.
42. Bradford HN, Krishnaswamy S. Meizothrombin is an unexpectedly zymogen-like variant of thrombin. J Biol Chem. 2012;287(36):30414-30425.
43. Papaconstantinou ME, Gandhi PS, Chen Z, Bah A, Di Cera E. Na+ binding to meizothrombin desF1. Cell Mol Life Sci. 2008;65(22):3688-3697.
44. Johnson DJ, Li W, Adams TE, Huntington JA. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J. 2006;25(9):2029-2037.
45. Persson E, Olsen OH. Allosteric activation of coagulation factor VIIa. Front Biosci. 2011;16:3156-3163.
46. Tsiang M, Paborsky LR, Li WX, et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry. 1996;35(51):16449-16457.
47. Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood. 2011;117(1):290-298.
48. Nakatomi Y, Tsuji M, Gokudan S, et al. Stable complex formation between serine protease inhibitor and zymogen: coagulation factor X cleaves the Arg393-Ser394 bond in a reactive centre loop of antithrombin in the presence of heparin. J Biochem. 2012;152(5):463-470.